Literature DB >> 16824058

Origin of hepatocellular carcinoma: role of stem cells.

Xiong-Zhi Wu1, Dan Chen.   

Abstract

The question of whether hepatocellular carcinoma (HCC) arises from the differentiation block of stem cells or dedifferentiation of mature cells remains controversial. Recently, researchers suggested that HCC may originate from the transdifferentiation of bone marrow cells. Interestingly, there are four levels of cells in the hepatic stem cell lineage: bone marrow cells, hepato-pancreas stem cells, oval cells and hepatocytes. Hematopoietic stem cells and the liver are known to have a close relationship in early development. Bone marrow stem cells could differentiate into oval cells, which could differentiate into hepatocytes and duct cells. The development of pancreatic and liver buds in embryogenesis suggests the existence of a common progenitor cell to both the pancreas and liver. Cellular events during hepatocarcinogenesis illustrate that HCC may arise from cells at various stages of differentiation in the hepatic stem cell lineage.

Entities:  

Mesh:

Year:  2006        PMID: 16824058     DOI: 10.1111/j.1440-1746.2006.04485.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

1.  New Approaches for Studying Alcoholic Liver Disease.

Authors:  Jun Xu; Xiao Liu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2014-09-14

Review 2.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

3.  The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in Alcoholic Liver Disease.

Authors:  Hsiao-Yen Ma; Jun Xu; Xiao Liu; Yunheng Zhu; Bin Gao; Michael Karin; Hidekazu Tsukamoto; Dilip V Jeste; Igor Grant; Amanda J Roberts; Candice Contet; Cedric Geoffroy; Binhai Zheng; David Brenner; Tatiana Kisseleva
Journal:  Curr Pathobiol Rep       Date:  2016-02-19

4.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.

Authors:  Kwang-Pyo Lee; Joo-Hyeon Lee; Tae-Shin Kim; Tack-Hoon Kim; Hee-Dong Park; Jin-Seok Byun; Min-Chul Kim; Won-Il Jeong; Diego F Calvisi; Jin-Man Kim; Dae-Sik Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

5.  CD34(+) Liver Cancer Stem Cells Were Formed by Fusion of Hepatobiliary Stem/Progenitor Cells with Hematopoietic Precursor-Derived Myeloid Intermediates.

Authors:  Changjun Zeng; Yanling Zhang; Su Cheol Park; Jong Ryeol Eun; Ngoc Tue Nguyen; Benjamin Tschudy-Seney; Yong Jin Jung; Neil D Theise; Mark A Zern; Yuyou Duan
Journal:  Stem Cells Dev       Date:  2015-08-19       Impact factor: 3.272

6.  Identification of cancer stem cell subpopulations of CD34(+) PLC/PRF/5 that result in three types of human liver carcinomas.

Authors:  Su Cheol Park; Ngoc Tue Nguyen; Jong Ryeol Eun; Yanling Zhang; Yong Jin Jung; Benjamin Tschudy-Seney; Artem Trotsyuk; Alexander Lam; Rajendra Ramsamooj; Yanghong Zhang; Neil D Theise; Mark A Zern; Yuyou Duan
Journal:  Stem Cells Dev       Date:  2015-01-26       Impact factor: 3.272

Review 7.  Cellular therapy for liver disease.

Authors:  Robert C Huebert; Jorge Rakela
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

8.  Bmi1 is required for hepatic progenitor cell expansion and liver tumor development.

Authors:  Lingling Fan; Chuanrui Xu; Chunmei Wang; Junyan Tao; Coral Ho; Lijie Jiang; Bing Gui; Shiang Huang; Matthias Evert; Diego F Calvisi; Xin Chen
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Autologous bone marrow stem cells in the treatment of chronic liver disease.

Authors:  Madhava Pai; Duncan Spalding; Feng Xi; Nagy Habib
Journal:  Int J Hepatol       Date:  2011-11-03

10.  Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit.

Authors:  Cyriac A Philips; Philip Augustine; Sasidharan Rajesh; Rizwan Ahamed; Tom George; Guruprasad Padsalgi; Rajaguru Paramaguru; Gopakumar Valiathan; Solomon K John
Journal:  J Clin Exp Hepatol       Date:  2019-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.